Results 201 to 210 of about 402,235 (309)

Placebo Effect of Caffeine on Physiological Parameters and Physical Performance. [PDF]

Nutrients
Ortiz-Sánchez D, Bravo-Sánchez A, Ramírez-delaCruz M, Abián P, Abián-Vicén J.   +4 more
europepmc   +1 more source

The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double‐blind, placebo‐controlled, crossover study in normal subjects [PDF]

, 2002
Peer Tfelt‐Hansen, Kaj N. Seidelin, Michael Stepanavage, Christopher Lines   +3 more
openalex   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Interleukin (IL)‐5, Eosinophils and IL‐5 Pathway Inhibitors in Eosinophilic Granulomatosis with Polyangiitis.

Arthritis &Rheumatology, Accepted Article.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

When does the placebo effect have an impact on network meta-analysis results? [PDF]

BMJ Evid Based Med
Nikolakopoulou A, Chaimani A, Furukawa TA, Papakonstantinou T, Rücker G, Schwarzer G.   +5 more
europepmc   +1 more source

A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: Effect on inflammation, psychopathology, cognition and lipid metabolism

, 2014
Brenda Vincenzi, Shannon Stock, Christina P. C. Borba, Sarah Cleary, Claire E. Oppenheim, Liana Petruzzi, Xiaoduo Fan, Paul M. Copeland, Oliver Freudenreich, Corinne Cather, David C. Henderson   +10 more
openalex   +1 more source

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

British Journal of Clinical Pharmacology, EarlyView.
Aims In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients ...
Xiaoying Zhao, Junjie Ding, Jiajia Zhao, Ling Zhang, Aburough Abegesah, Yu‐qian Zhang, Cathy O'Brien, Gary J. Doherty, Allen C. Chen, KyoungSoo Lim, Song Ren, Peiming Ma, Diansong Zhou   +12 more
wiley   +1 more source

Homeopathy is not placebo effect: proof of the scientific evidence for homeopathy in open access trilingual e-book. [PDF]

Clinics (Sao Paulo)
Teixeira MZ.
europepmc   +1 more source

Double-Blind, Randomized, Placebo-Controlled Clinical Trial Evaluating the Effect of Antioxidants on DNA Fragmentation Index in Men with Idiopathic Oligoasthenoteratozoospermia

Ameet Patki, Rohit Shelatkar, Monica Singh, Sweta Agarwal, Meenakshi Venugopal, Shashikant Umbardand, Apoorva Reddy, Priya Kannan, Srilatha Gorthi, Gautam Khastgir, Anita Kulshreshtha, Gayatri Ganu   +11 more
openalex   +2 more sources